ライフサイエンスコーパス: transplantation therapy

1 ay provide an alternative to donor lungs for transplantation therapy.

2 and targeted injection of MSCs can optimize transplantation therapy.

3 ction represents a promising new approach to transplantation therapy.

4 ecome a prominent and pervasive influence on transplantation therapy.

5 that is crucial to the effectiveness of the transplantation therapy.

6 l pulp tissues, are potential tools for cell transplantation therapy.

7 beneficial to improve the outcomes for islet transplantation therapy.

8 ntial for clinical application of liver cell transplantation therapy.

9 possibilities for in vitro research and cell transplantation therapy.

10 permeability and immune-protection for islet transplantation therapy.

11 derlie beta cell failure and/or hamper islet transplantation therapy.

12 ood should make them valuable candidates for transplantation therapy.

13 , may impose two major barriers in LCAs cell transplantation therapy.

14 of ex vivo expanded hematopoietic cells for transplantation therapy.

15 fering with BTLA signaling in post-stem cell transplantation therapies.

16 afe source of endodermal-derived tissues for transplantation therapies.

17 , providing an unlimited source of cells for transplantation therapies.

18 otropic liver transplantation and hepatocyte transplantation therapies.

19 creen and toxicity testing, and for cellular transplantation therapies.

20 ns ranging from in vitro diagnostics to cell transplantation therapies.

21 em (hES) cells offer the opportunity for new transplantation therapies.

22 n and suggest a potential role for stem cell transplantation therapies.

23 , as a source of human DA neurons for use in transplantation therapies.

24 a novel source of cells for transfusion and transplantation therapies.

25 ifferentiation and may play a role in future transplantation therapies.

26 unlimited supply of specific cell types for transplantation therapies.

27 in vitro that are needed for autologous HSC transplantation therapies.

28 d opportunity to generate new beta-cells for transplantation therapy and drug screening.

29 logies, is a promising approach for cellular transplantation therapy and for in vitro disease modelin

30 Fetal cell transplantation therapies are being developed for the tr

31 s to create patient-specific donor cells for transplantation therapy, avoiding immunorejection, a maj

32 e development of future dopamine neuron cell transplantation therapy-based approaches, indicating tha

33 ion about the use of totipotent ESCs in cell transplantation therapy, because they may act as an unan

34 unlimited source of cells suitable for such transplantation therapy can be derived from embryonic st

35 n this review we examine how stem cell-based transplantation therapies compare with these novel and e

36 The hope of developing new transplantation therapies for degenerative diseases is l

37 the design of stem or progenitor cell-based transplantation therapies for HIV infection.

38 new avenues for basic research and potential transplantation therapies for neurological diseases.

39 s the development of personalized iPSC-based transplantation therapies for retinal disease.

40 Approaches to successful cell transplantation therapies for the injured brain involve

41 ial damage, which suggests their use in cell transplantation therapy for cardiomyopathy.

42 ells will need to be identified if effective transplantation therapy for chronic pain is to be develo

43 Transplantation therapy for human diabetes is limited by

44 R-HLA mismatching in hematopoietic stem cell transplantation therapy for leukemia and new, more speci

45 UCB increases access to transplantation therapy for many patients unable to iden

46 to successful allogeneic hematopoietic cell transplantation therapy for the treatment of hematologic

47 Stem cell-based regenerative (transplantation) therapies for PD have not been implemen

48 y mAb has been used for immunosuppression in transplantation, therapy for leukemia, and autoimmune di

49 great success including those awaiting liver transplantation, therapy has been extended to patients w

50 hematopoietic cell culture technologies for transplantation therapies have progressed significantly

51 Transplantation therapies have revolutionized care for p

52 l role of human embryonic stem (ES) cells in transplantation therapy have often overshadowed their po

53 opments in the application of stem cells for transplantation therapies in neurodegenerative diseases.

54 e for the future application of hES cells in transplantation therapies in which the use of aneuploid

55 nted cell source for drug discovery and cell transplantation therapy in diabetes.

56 oach for enhancing the effectiveness of cell transplantation therapy in ischaemic stroke.

57 ukin 6 facilitates the effectiveness of cell transplantation therapy in ischaemic stroke.

58 afe approach to enhance the effectiveness of transplantation therapy in ischemic stroke.

59 Noonan syndrome and for improving stem cell transplantation therapy in Noonan-syndrome-associated le

60 tial hinderance to the use of such cells for transplantation therapy of insulin-dependent diabetes me

61 resent an alternative to isolated islets for transplantation therapy of type 1 diabetes.

62 This may have applications in transplantation therapy or in the treatment of diseased

63 a strategy for extending the availability of transplantation therapy, particularly for older patients

64 nt quality of care including access to renal transplantation therapy (RTT).

65 As a prerequisite to transplantation therapy, strategies must be developed to

66 World Kidney Day is a call to deliver transplantation therapy to the 1 million people a year w

67 may also improve the chances for successful transplantation therapy via earlier reinduction therapy,